
Soleno Therapeutics, Inc.
NASDAQ:SLNO
Overview | Financials
Company Name | Soleno Therapeutics, Inc. |
Symbol | SLNO |
Currency | USD |
Price | 76.78 |
Market Cap | 3,869,243,642 |
Dividend Yield | 0% |
52-week-range | 36.93 - 78.555 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Anish Bhatnagar M.D. |
Website | https://soleno.life |
An error occurred while fetching data.
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD